<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>52</patient-age><report-id>PHHO2011NO14507</report-id><gender>male</gender><reactions><reaction>Cardiac infarction</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>AMN107</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>GLIMEPIRIDE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>METFORMIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>APROVEL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>NEXIUM</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>OXIS</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>AEROBEC</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>BRICANYL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ANTIHYPERTENSIVES</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Gastrointestinal stromal tumour</indication></indications><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Norway</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053165_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134148</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>5</safetyreportversion>
		<safetyreportid>PHHO2011NO14507</safetyreportid>
		<primarysourcecountry>NO</primarysourcecountry>
		<occurcountry>NO</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-10</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2011-08-25</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-06</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHO2011NO14507</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<linkedreport>
			<linkreportnumb>PHHO2011NO05342</linkreportnumb>
		</linkedreport>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Kirsten</reportergivename>
			<reportermiddlename>Sundby</reportermiddlename>
			<reporterfamilyname>Hall</reporterfamilyname>
			<reporterorganization>Radiumhospitalet</reporterorganization>
			<reporterdepartment>Division of Cancer</reporterdepartment>
			<reportercountry>NO</reportercountry>
			<qualification code="1">Physician</qualification>
			<sponsorstudynumb>CAMN107G2301</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>--</patientinitial>
			<patientinvestigationnumb>6</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19590326</patientbirthdate>
			<patientheight>180</patientheight>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Percutaneous coronary intervention</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Diabetes mellitus</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Tobacco user</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Myocardial infarction</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Cardiac infarction</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Myocardial infarction</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Myocardial infarction</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20110824</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20110829</reactionenddate>
				<reactionduration>6</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>161</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>1</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="1">recovered/resolved</reactionoutcome>
			</reaction>
			<test>
				<testname>Arteriogram coronary</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Blood test</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Catheterisation cardiac</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Electrocardiogram</testname>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>AMN107</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugcumulativedosagenumb>128800</drugcumulativedosagenumb>
				<drugcumulativedosageunit code="003">milligrams</drugcumulativedosageunit>
				<drugdosagetext>400 mg, BID</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Gastrointestinal stromal tumour</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2011-03-17</drugstartdate>
				<drugstartperiod>161</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>1</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2011-08-24</drugenddate>
				<drugtreatmentduration>161</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Myocardial infarction</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>GLIMEPIRIDE</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<drugstructuredosagenumb>2</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>2 mg, QD</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>GLIMEPIRIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>METFORMIN</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<drugstructuredosagenumb>1000</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>1000 mg, BID</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>METFORMIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>APROVEL</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>300 mg, QD</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>IRBESARTAN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>NEXIUM</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<drugstructuredosagenumb>40</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>40 mg, QD</drugdosagetext>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ESOMEPRAZOLE MAGNESIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>OXIS</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>FORMOTEROL FUMARATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>AEROBEC</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>BECLOMETASONE DIPROPIONATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>BRICANYL</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>TERBUTALINE SULFATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>ANTIHYPERTENSIVES</medicinalproduct>
				<obtaindrugcountry>NO</obtaindrugcountry>
				<drugauthorizationcountry>NO</drugauthorizationcountry>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>NO INGREDIENTS/SUBSTANCES</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHO2011NO14507, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>report received on 25 Aug 2011, from clinical study CAMN107G2301. This 52-year old male subject (centre number 0461, subject number 6) was enrolled in a randomised, open label, multi center phase III study to evaluate the efficacy and safety of <Semaphore x="928154" class="Medicine" value="nilotinib" score="0.87" ID="278855">nilotinib </Semaphore>versus <Semaphore x="699336" class="Medicine" value="imatinib" score="0.87" ID="252378">imatinib </Semaphore>in <Semaphore x="2102861" class="Occupation" value="Legal Occupations" score="1.00" ID="C97637">adult </Semaphore>subjects with unresectable or <Semaphore x="2224523" class="Disease or Finding" value="Metastatic Neoplasm" score="1.00" ID="C3261">metastatic <Semaphore x="1965977" class="Disease or Finding" value="Gastrointestinal Neoplasm" score="1.00" ID="C3052">gastrointestinal stromal tumors </Semaphore></Semaphore>(<Semaphore x="1967459" class="Disease or Finding" value="Gastrointestinal Stromal Tumor" score="1.00" ID="C3868">GIST</Semaphore>). The primary <Semaphore x="51345" class="Medicine" value="Aim" score="0.49" ID="188966">aim </Semaphore>of the study is to <Semaphore x="1803212" class="Procedure" value="Comparison of Screening Methods" score="1.00" ID="C62743">compare </Semaphore>progression <Semaphore x="1882188" class="Disease or Finding" value="Empty Sella Syndrome" score="1.00" ID="C84686">free </Semaphore>survival (<Semaphore x="2425244" class="Disease or Finding" value="Progression of Multiple Myeloma or Plasma Cell Leukemia" score="1.00" ID="C70643">PFS</Semaphore>) of <Semaphore x="928154" class="Medicine" value="nilotinib" score="0.87" ID="278855">nilotinib </Semaphore>and <Semaphore x="699336" class="Medicine" value="imatinib" score="0.87" ID="252378">imatinib </Semaphore>when used as <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">therapy </Semaphore>of unresectable and/or metastatic <Semaphore x="1967459" class="Disease or Finding" value="Gastrointestinal Stromal Tumor" score="1.00" ID="C3868">GIST </Semaphore>in subjects either who have not received <Semaphore x="2424313" class="Procedure" value="Prior Therapy" score="1.00" ID="C16124">prior therapy </Semaphore>with TKIs or who have recurrent <Semaphore x="1967459" class="Disease or Finding" value="Gastrointestinal Stromal Tumor" score="1.00" ID="C3868">GIST </Semaphore>after stopping adjuvant <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="699336" class="Medicine" value="imatinib" score="0.87" ID="252378">imatinib</Semaphore>.The subject's medical history included <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes</Semaphore>, <Semaphore x="3280826" class="MedDRA LLT" value="Tobacco user" score="1.00" ID="10057581">smoker</Semaphore>, and <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension</Semaphore>. The subject had family <Semaphore x="2331974" class="Disease or Finding" value="Old Myocardial Infarction" score="1.00" ID="C35205">history of <Semaphore x="3120463" class="MedDRA LLT" value="Myocardial infarction" score="1.00" ID="10028596">myocardial infarction</Semaphore></Semaphore>. Concomitant medications included <Semaphore x="623055" class="Medicine" value="glimepiride" score="0.49" ID="251607">glimepiride</Semaphore>, <Semaphore x="857859" class="Medicine" value="metFORMIN" score="0.49" ID="279450">metformin</Semaphore>, Aprovel, <Semaphore x="917603" class="Medicine" value="NexIUM" score="0.49" ID="242894">Nexium</Semaphore>, <Semaphore x="601266" class="Medicine" value="formoterol" score="0.49" ID="251425">formoterol </Semaphore>(oxis) inhalation, AeroBec inhalation, bricanyl inhalation, and antihypertensives. The subject was randomized to receive <Semaphore x="928154" class="Medicine" value="nilotinib" score="0.87" ID="278855">nilotinib </Semaphore>in the core phase and received his first dose of study medication on 17 Mar 2011. On 24 Aug 2011, the subject experienced <Semaphore x="2010398" class="AnatomicStructure" value="Heart" score="1.00" ID="C12727">cardiac </Semaphore><Semaphore x="3032386" class="MedDRA LLT" value="Infarction" score="1.00" ID="10061216">infarction</Semaphore>, which <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">resulted </Semaphore>in <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalisation </Semaphore>on the same day. One day before <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalisation</Semaphore>, the subject experienced <Semaphore x="2010398" class="AnatomicStructure" value="Heart" score="1.00" ID="C12727">cardiac </Semaphore><Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain </Semaphore>(tightness or squezzing in the <Semaphore x="1762050" class="AnatomicStructure" value="Chest" score="1.00" ID="C25389">chest</Semaphore>) and <Semaphore x="1870759" class="Disease or Finding" value="Dyspnea" score="1.00" ID="C2998">dyspnea </Semaphore>during sleep. On an unspecified date, <Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">ECG </Semaphore>(<Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">electrocardiogram</Semaphore>) ,coronaryangiography/cardiac catherization and <Semaphore x="2817940" class="MedDRA LLT" value="Blood test" score="1.00" ID="10061726"><Semaphore x="2013340" class="Procedure" value="Hematology Test" score="1.00" ID="C49286">blood <Semaphore x="1787567" class="Disease or Finding" value="Clinical Test Result" score="1.00" ID="C77140">test </Semaphore></Semaphore>
     <Semaphore x="2091429" class="Disease or Finding" value="Laboratory Test Result" score="1.00" ID="C36292">
      </Semaphore></Semaphore>
    <Semaphore x="2091429" class="Disease or Finding" value="Laboratory Test Result" score="1.00" ID="C36292">
     <Semaphore x="1787567" class="Disease or Finding" value="Clinical Test Result" score="1.00" ID="C77140">was done (results </Semaphore></Semaphore>not available). The study medication was temporarily interrupted on 25 Aug 2011 due to the event. The subject underwent <Semaphore x="1814460" class="Procedure" value="Coronary Angiography" score="1.00" ID="C100085">coronary <Semaphore x="2742940" class="MedDRA LLT" value="Angiogram" score="1.00" ID="10061637">angiography </Semaphore></Semaphore>with <Semaphore x="2387781" class="Procedure" value="Percutaneous Coronary Intervention" score="1.00" ID="C99521">PCI </Semaphore>(<Semaphore x="2387781" class="Procedure" value="Percutaneous Coronary Intervention" score="1.00" ID="C99521">percutaneous coronary intervention</Semaphore>) and treated with <Semaphore x="383365" class="Medicine" value="clopidogrel" score="0.49" ID="253930">clopidogrel </Semaphore>hydrogen sulfate, <Semaphore x="530375" class="Medicine" value="Enoxaparin" score="0.49" ID="279302">enoxaparin</Semaphore>, acetylsalicylic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid </Semaphore>and <Semaphore x="869626" class="Medicine" value="Metoprolol" score="0.49" ID="280141">metoprolol</Semaphore>. The subject completely recovered from the event on 29 Aug 2011 and discharged on the same date. The event was considered serious (<Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalisation</Semaphore>) by the investigator.The investigator did not suspect a relationship between the event and the study medication.Follow up report received on 13 Sep 2011: Symptoms of the <Semaphore x="2032443" class="Disease or Finding" value="Hospitalization Event" score="1.00" ID="C80481">event, <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalisation </Semaphore></Semaphore>details, action taken with the study medication, concomitant medication details, <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>details and <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event updated.Follow up report received on 23 Sep 2011: Causality of the event was updated.Follow up <Semaphore x="1862781" class="Race" value="Dominican" score="1.00" ID="C67117">DR </Semaphore>received on 03 Nov 2011: Event causality was updated.Follow up <Semaphore x="2081060" class="Disease or Finding" value="Ischemic Heart Disease" score="1.00" ID="C50625">ischemic heart disease </Semaphore>was received on 06 Dec 2012: Updated medical history, family history, concomitant medications, and clinical course of the event including laboratory data.</narrativeincludeclinical>
				<sendercomment>Medical review and assessment complete. Novartis concurs with the investigator's assessment.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>